Intentional Weight Loss Linked to Lowered Endometrial Cancer Risk

Article

Intentional weight loss can lower the risk of endometrial cancer in postmenopausal women, according to a new study. This was especially true of obese women who lost weight.

Intentional weight loss can lower the risk of endometrial cancer in postmenopausal women, according to a new study. This was especially true of obese women who lost weight.

“Although endometrial cancer is the cancer most strongly associated with obesity, information about the effects of weight loss in postmenopausal women on subsequent endometrial cancer incidence is limited,” wrote study authors led by Juhua Luo, PhD, of Indiana University in Bloomington. Previous work has suggested that unintentional weight loss can be associated with increased morbidity, but most studies have not looked into the influence of intentionality.

The new study included 36,794 women included in the Women’s Health Initiative; all were aged 50 to 79 years at enrollment, and body weight and body mass index (BMI) were calculated at baseline and at year 3. Stable weight indicated no more than 5% gain or loss, while loss and gain referred to 5% or more from baseline; a self-report at year 3 determined intentionality of weight change, and this was correlated with risk of endometrial cancer diagnosis. The results were published online ahead of print in the Journal of Clinical Oncology.

Over a mean follow-up period of 11.4 years, 566 women were diagnosed with endometrial cancer. After adjustment for baseline BMI and other factors, women who had weight loss of 5% or greater had significantly lower risk for endometrial cancer than women with stable weight, with a hazard ratio of 0.71 (95% CI, 0.54–0.95). This was more pronounced among women whose weight loss was deemed intentional; in those women, the HR for endometrial cancer was 0.60 (95% CI, 0.42–0.86).

The effect was strongest in women who were obese (BMI ≥ 30 kg/m2) at baseline. In those women who intentionally lost at least 5% of their body weight the HR for endometrial cancer was 0.44 (95% CI, 0.25–0.78). There was no significant effect seen in normal weight or overweight individuals.

There was an increased risk for the malignancy in women with a weight gain of at least 10 pounds who had not received hormone therapy, but not in those who had.

“These findings should motivate programs for weight loss in obese postmenopausal women,” the authors concluded.

Jennifer Ligibel, MD, an American Society of Clinical Oncology (ASCO) expert at Dana-Farber Cancer Institute who was not involved in the study, agreed in a press release that this would support the development of weight loss programs as part of a cancer prevention strategy. “There have been more than a thousand studies linking obesity to an increased risk of endometrial and other cancers, but almost none that look at the relationship between weight loss and cancer risk,” she said. “This study tells us that weight loss, even later in life, is linked to a lower risk of endometrial cancer.”

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Ritu Salani, MD, discussed investigational endometrial cancer treatment options for patients with varying subtypes of endometrial cancer.
The second interim analysis of the phase 3 RUBY trial found the safety profile was consistent with the first interim analysis and no new deaths due to AEs were observed.
Related Content